We found that for a broad population of people with type 2 diabetes mellitus, SGLT-2 inhibitors were more effective second line treatments in routine clinical practice compared with DPP-4 inhibitors or sulfonylureas in improving HbA1c levels, BMI, and systolic blood pressure. Here, SLC5A2 is linked to diabetes mellitus.